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Aim: to study the effect on plasma vascular endothelial growth factor (VEGF) levels of oral purified flavonoid fraction
treatment for sixty days in patients with chronic venous disease (CVD).
Material and methods: twenty patients ‘CEAP’ (clinical stage 2–4) with chronic venous disease were included. Duplex
ultrasonography was used to assess the venous disease. Patients were treated for 60 days with DaflonÒ 500 mg twice
daily. Blood was collected from a foot vein immediately before starting treatment and within one week of stopping
treatment. Plasma VEGF levels were determined using a sandwich ELISA method.
Results: VEGF levels decreased in patients with stage C4 CVD after treatment with purified micronised flavonoid
fraction treatment (98 pg/ml to 57 pg/ml). The levels of VEGF in patients with skin changes were significantly higher
(98 pg/ml) than those with normal skin (9 pg/ml; p=<0.001 Wilcoxon).
Conclusions: plasma VEGF levels were much higher in patients who have skin changes of CVD. Plasma VEGF protein
decreases in patients with CVD-induced dermatologic changes following treatment with purified micronised flavonoid
fraction.
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Introduction involved physiologically in the angiogenesis of heal-
ing. It is also involved in tumour angiogenesis. It is
Presently there are no reliable markers either to assess a very potent microvascular permeability-increasing
factor as well.4 It is a glycoprotein secreted by a varietythe effectiveness of treatment of chronic venous disease
(CVD) or to help in its prognosis. Many patients are of cells including smooth-muscle cells, monocytic cells
and keratinocytes.5 Its expression is dependent onworried about the long-term sequelae of their venous
disease and do not want surgery merely for ap- increased mRNA synthesis and increased tran-
scription.6 Any tissue injury, especially hypoxic injury,pearance’s sake. Markers of venous disease include
clinical, hand-held Doppler, duplex, plethysmography could be a potent stimulus for its expression.
Abnormally increased and prolonged exposure to(air, photo, strain gauge), capillary microscopy and
tonometric criteria. Many assessments are subjective VEGF could have local deleterious effects. VEGF is
strongly expressed by epidermal keratinocytes duringand may be unreliable. Duplex examination after ther-
apy may indicate success in the short term but may wound-healing, in psoriasis, in skin with ultra-violet
burns, lesions of rheumatoid arthritis and in bullousnot predict future recurrences or the course of skin
complications. diseases such as erythema multiforme and bullous
pemphigoid. All of these disorders are characterisedInflammatory processes are regarded as important
in the pathogenesis of skin changes seen in CVD.1 by increased microvascular permeability and angio-
genesis. We have previously shown up-regulation ofIncreased leucocyte presence has been shown in the
skin and the vein wall itself. In the chronic stages there VEGF expression in the skin and plasma of patients
with CVD (author’s own unpublished data and else-is a reparative tissue response that exists alongside
the inflammatory response.2 Many growth factors are where).7,13 This expression is more marked in patients
with clinical stage C4 disease.8involved in the reparative response.3 Vascular endo-
thelial growth factor (VEGF) is one of the molecules Various compounds have been used for the treat-
ment of CVD. These include fibrinolytics, methyl-
* Please address all correspondence to: Department of Surgery, 1st xanthines, prostaglandins and flavonoids. AlthoughFloor Jules-Thorne Building, The Middlesex Hospital, Mortimer
Street, London W1N 8AA, U.K. none of these cure the valvular insufficiency, some
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Table 1. Distribution of the patients according to their CEAP stage and anatomical
localisation of CVD. There are equal number of patients with and without skin
changes (n=10). Two patients had reflux localised to “minor” tributaries that did not
relate to either of the two major superficial systems. Perforator incompetence is not
listed separately because none of the patients had isolated perforator incompetence.
CEAP Stage SVI DVI SVI/DVI LSV SSV LSV/SSV Other
C2 3 – – 2 1 1 1
C3 4 – 3 2 – 2 1
C4 7 1 2 5 – 4 –
ALL* (M:F) 14 (2:12) 1 (M) 5 (3:2) 9 (3:6) 1 (F) 7 (3:4) 2 (F)
*Median age 58, range (39–82).
can ameliorate the complications of CVD. A purified for 30 minutes. We had shown previously that standing
micronised flavonoid fraction (DaflonÒ500, Servier supported predictably produces venous pressures at
Laboratories, France) has been used in France and the ankle level of 70–90 mmHg. This is relatively con-
Germany for the treatment of CVD for some time. stant regardless of the status of the venous in-
Daflon consists of 90% diosmin (3¢,5,7-trihydroxy-4¢- sufficiency, since it is hydrostatically generated. This
methoxyflavone-7-rhamnoglucoside; C28H32O15) and was followed by a further 10-minute period of lying
10% hesperidin flavonoids (3¢,5,7-trihydroxy-4¢-me- supine. Blood was collected at the end of each period,
thoxyflavanone-7-rhamnoglucoside. The aim of our using EDTA as the anticoagulant. Plasma was sep-
study was to the response of plasma VEGF levels in arated by spinning the blood sample at 2000 r.p.m. for
CVD to oral flavonoid treatment for sixty days. 10 minutes. We have shown previously that standing
produces pressures of 70–80 mmHg in the foot veins.9
Because this pressure is generated hydrostatically, it
is irrespective of the presence of venous insufficiency,Material and Methods
which would be important if the patients were ex-
ercising during the standing period. It has long beenEthics committees consent for the study was obtained
recognised that abnormalities in venous pressure infrom UCL Medical School Committee for medical
patients with lower-limb venous disease only becomeethics. Patients who gave their written informed con-
apparent during exercise.sent to the study were included. Twenty patients with
At D60 evaluation was performed of the globalchronic venous disease, clinical stage 2–4 were re-
efficacy of the drug in relieving symptoms. Differencescruited from the vascular clinic at the Middlesex Hos-
between the two sets of results from plasma samplespital. All patients had a venous duplex examination
were determined statistically. Compliance with takingwithin the previous eight weeks to establish venous
the drug and any adverse effects were taken intodisease and to localise it anatomically. The patients
account.were asked to attend the department on three separate
We used the clinical criteria of the ‘CEAP’ (Clinical,occasions at two weeks before treatment (D-15), the
Etiologic, Anatomic, Pathologic) classification to clas-day of starting treatment (D0) and after finishing
sify our patients.8 Patients with chronic venous diseasetreatment (D60). At D-15 a medical history was taken
(clinical stage 2–5) proved by duplex ultrasonographyand an examination performed. All patients had a full
were selected. All patients wore class II (U.K.) supportblood count, serum urea and electrolyte/liver function
stockings and continued to do so during the study.tests. At D0 and D60 evaluation of specific venous
Inclusion criteria were patient age above 18 years,symptoms was also performed. At D0 and D60 speci-
patients affected with Hawaii stage C2 to C4 or C6mens (30 ml each) were taken from foot veins before
with a healed ulcer for at least 4 weeks, psychologicaland after standing the patient supported for 30 min-
stability and motivation.utes. DaflonÒ 500 mg twice daily (Servier, France) was
Exclusion criteria for the study were as following.administered for 60 days starting at day 0.
History of alcohol or drug abuse, known history ofA foot vein or the long saphenous vein at the ankle
allergy or intolerance to diosmin or any other veno-was cannulated using an 18-G cannula (Vasculon 2,
tonic agent, active venous ulceration, diabetes mellitus,Viggo-Spectramed, Helsingborg, Sweden) and blood
impaired hepatic function (ALT or AST 3-fold abovesamples were taken from each subject before and after
the normal limit) or impaired renal function (seruma period of experimental venous hypertension. The
subject first stood supported, with minimal movement creatinine >120 lmol/l). Any concomitant active
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Table 2. Median plasma VEGF levels (pg/ml) in patients with (C4) using the Wilcoxon matched pair ranking test. The
and without skin changes (C2/C3). The respective values before values obtained before and after a period of posturaland after sixty days’ treatment with flavonoids are shown. This
table shows the combined values in each group before and after venous hypertension were combined together. Stat-
a 30-minute period of standing up. Values in parentheses are istical analyses were performed on both subsets of
interquartile ranges. patients (with/without skin changes) together as well
Before treatment After treatment as separately.
C2/C3 9 (5–25) 10 (5–26)
C4 ‡98 (64–113) ‡57 (37–95)
p=<0.001 (Wilc) p=<0.001 (Wilc) ResultsAll patients 47 (17–101) 29 (8–56)
‡ p=<0.02 (Wilcoxon). We found a decrease in the levels of plasma levels
of VEGF in patients with CVD after treatment with
purified micronised flavonoid fraction treatment. Thedisease or abnormality in laboratory test (judged as
difference was found in patients with dermatologicalclinically significant by the investigator). Patients
signs of CVD. The levels obtained both before as welltreated with other vasoactive drugs within the 15
as after periods of standing were decreased in a verydays prior to inclusion, patients with an acute/chronic
similar fashion (see Tables 1 and 2).inflammatory or infectious disease, deep-venous
The levels of VEGF in patients without der-thrombosis within the past 12 months, superficial-
matological changes as compared to C4 patients werevenous thrombosis within 3 weeks. Patients using
much lower. This represented a four-fold to ten-foldsteroids, NSAIDs, other “vaso-active” drugs, Vitamins
increase in plasma levels in patients who had overtA, C and E or anticoagulants and those with previous
dermatological changes (Tables 1 and 2). There werepoor compliance to treatment as well as participants
two patients with very high levels of plasma VEGF inof a trial within the past three months were excluded.
the C2/C3 group.Pregnancy, breast-feeding or lack of active con-
The median compliance rate with Daflon was 98%traception also excluded the patient.
(range 90%–103%). Seven patients experienced minorAssay of VEGF165 protein was performed using a side-effects (loose motions three, headache two, andsandwich ELISA technique. A “Quantikine” kit sup-
faintness one). All recovered spontaneously and pre-plied by R&D systems (4–10 The Quadrant, Barton
ferred to complete the study.Lane, Abingdon, Oxon OX14 3YS, U.K.) was used.
Plasma levels were read from standard curves obtained
by plotting mean absorbency for standards.
The test used measured levels of VEGF165. This is Discussion
one of the four 4 transcripts encoding mature mono-
meric VEGF (viz. VEGF121, VEGF165, VEGF189, VEGF206). We found that plasma VEGF decreases appreciably
in patients with skin changes following sixty days’VEGF121 and VEGF165 are diffusible proteins that are
secreted into the medium. The other two are mostly therapy with oral purified micronised fraction. No
significant effect was seen in this study in patientsbound to heparin containing proteoglycans in the
matrix. Results obtained for naturally occurring without dermatological manifestations. C4 patients
exhibited significantly higher levels of VEGF (Fig. 1).human VEGF and the recombinant VEGF121 showed
linear curves that were parallel to the standard curves Daflon is reported to cause symptomatic improvement
in patients with a spectrum of CVD.11 The lack ofobtained using the Quantikine kit standards.
There were an equal number of patients with and any effect on plasma VEGF in patients without skin
changes is interesting. It is interesting to note thatwithout skin changes (n=10). Seven patients in each
group had superficial venous insufficiency (SVI) only. in a previous study we showed micronised purified
flavonoid fraction to cause a similar reduction in leuco-Of the remaining six patients the majority (5) had
combined SVI and deep venous insufficiency (DVI). cyte adhesion molecule expression in both subsets of
patients.12Most patients either had long saphenous (LSV) in-
volvement (n=9) or combined LSV and short sa- This study was a follow-on from our previous stud-
ies which had shown correlation of high VEGF levelsphenous (SSV) involvement (n=7). Two patients had
CVD involving neither of the two major superficial in CVD in specimens of foot-vein blood.7 We had also
shown that induced venous hypertension can causeanatomic systems.
The results of plasma VEGF obtained before and an increase in plasma VEGF levels.13 In the present
study we found that both supine and standing levelsafter the 60-day flavonoid therapy were compared
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The large difference between VEGF levels in C2/C3
and C4 patients could represent different stages of
development of the dermatological changes. In the
initial stages leucocyte-mediated damage could be the
predominant event. Later on the reparative process
(increased VEGF) may become more important and
may co-exist with continuing skin damage. There were
two patients with higher levels of VEGF in the C2/
C3 group. One explanation for this could be that these
had incipient skin changes that were more advanced
than was clinically apparent. Larger scale trials may
provide answers to these questions. If further studies
indicate that high plasma levels of VEGF indicate
impending skin changes, it may provide us with a
useful tool for prediction. Similarly, if it could be
demonstrated that absence of a fall in VEGF levels
following therapy predicts a higher chance of re-
currence, this may be used as a marker of success of
the treatment. We are following these up to look for
Fig. 1. Shows comparisons of plasma VEGF levels in patients before development of clinically obvious skin changes.and after 60 days of flavonoid treatment. Values shown are before
In conclusion, plasma VEGF activity decreases in(A) and after (B) a 30-minute period of standing. The bold lines join
the two respective median values; differences between these values patients with CVD-induced dermatologic changes fol-
were not significant. Vertical bars represent interquartile ranges. lowing treatment with purified micronised flavonoid
fraction. VEGF protein levels are much higher in these
of VEGF were equally affected by flavonoid therapy. patients as compared to those with simple CVD. Fur-
We did not observe as great a difference between ther studies are needed to determine the medical
patients with and without skin changes in that study. significance of these findings. The role of circulating
We are currently undertaking a larger prospective trial VEGF as a marker for skin complications in these
to try and clarify this issue. We are also undertaking patients needs to be explored further.
studies to determine if the VEGF levels in blood from
an arm vein are different in these patients.
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